Stock QGEN QIAGEN N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Qiagen N.V.

Equities

QGEN

NL0015001WM6

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
43.26 USD +1.45% Intraday chart for Qiagen N.V. -1.07% -3.38%
May. 31 Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test MT
May. 31 Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The firm trades with high earnings multiples: 23.47 times its 2024 earnings per share.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
QIAGEN N.V. Stock Qiagen N.V.
-3.38% 9.6B
A
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. Ratings Qiagen N.V.